Nxera Earns $15M As Neurocrine Launches Global Phase 3 Trial Of Schizophrenia Drug NBI-‘568

Nxera Pharma Co., Ltd. announced that Neurocrine Biosciences, its strategic partner, has begun dosing the first patient in a Phase 3 registrational trial of NBI-1117568 (NBI-‘568) for schizophrenia. This milestone has triggered a payment of US$15 million to Nxera, which will be recorded as revenue in the company’s second-quarter financials for 2025.

The trial, which began in May 2025, marks a critical phase in the global development program of NBI-‘568. Designed as a double-blind, placebo-controlled study, it will assess the drug’s efficacy and safety in adult patients diagnosed with schizophrenia who are experiencing acute symptom relapse or exacerbation. The study is expected to enroll around 280 participants across multiple global sites.

The trial is mainly designed to evaluate the impact on symptoms by using the Positive and Negative Syndrome Scale (PANSS) and, secondly, to assess how much better patients are by looking at the Clinical Global Impression of Severity (CGI-S). These outcomes will help determine the drug’s potential as a new treatment option for schizophrenia.